Abstract:Clustered regularly interspaced palindromic repeats (CRISPR) is a gene editing tool with tremendous therapeutic potential. Recently, ribonucleoprotein (RNP) complex‐based CRISPR systems have gained momentum due to their reduction of off‐target editing. This has coincided with the emergence of extracellular vesicles (EVs) as a therapeutic delivery vehicle due to its low immunogenicity and high capacity for manipulation. EVs are cell‐derived membranous nanoparticles which mediate the intercellular transfer of molecular components. Current technologies achieve CRISPR RNP encapsulation into EVs through EVs biogenesis, thereby avoiding unnecessary physical, chemical or biological manipulations to the vesicles directly. Herein, we identify sixteen EVs‐based CRISPR RNP encapsulation strategies, each with distinct genetic features to encapsulate CRISPR RNP. According to the molecular mechanism facilitating the encapsulation process, there are six strategies of encapsulating Cas9 RNP into virus‐like particles based on genetic fusion, seven into EVs based on protein tethering, and three based on sgRNA‐coupled encapsulation. Additionally, the incorporation of a targeting moiety to the EVs membrane surface through EVs biogenesis confers tropism and increases delivery efficiency to specific cell types. The targeting moieties include viral envelope proteins, recombinant proteins containing a ligand peptide, single‐chain fragment variable (scFv) antibodies, and integrins. However, current strategies still have a number of limitations which prevent their use in clinical trials. Among those, the incorporation of viral proteins for encapsulation of Cas9 RNP have raised issues of biocompatibility due to host immune response. Future studies should focus on genetically engineering the EVs without viral proteins, enhancing EVs delivery specificity, and promoting EVs‐based homology directed repair. Nevertheless, the integration of CRISPR RNP encapsulation and tropism technologies will provide strategies for the EVs‐based delivery of CRISPR RNP in gene therapy and disease treatment.

Efficient RNA drug delivery using red blood cell extracellular vesicles

Therapeutic potential of RNA-enriched Extracellular Vesicles 1: The next generation in RNA delivery via biogenic nanoparticles

Efficient and highly reproducible production of red blood cell-derived extracellular vesicle mimetics for the loading and delivery of RNA molecules

Extracellular vesicles engineered with valency-controlled DNA nanostructures deliver CRISPR/Cas9 system for gene therapy

Delivery of therapeutic RNA by extracellular vesicles derived from Saccharomyces cerevisiae for Medicine Applications

Direct cytoplasmic delivery of RNAi therapeutics through a non-lysosomal pathway for enhanced gene therapy

Engineering extracellular vesicles to deliver CRISPR ribonucleoprotein for gene editing

Current and prospective strategies for advancing the targeted delivery of CRISPR/Cas system via extracellular vesicles

CRISPR/Cas9 delivery strategies with engineered extracellular vesicles

Novel endogenous engineering platform for robust loading and delivery of functional mRNA by extracellular vesicles

Red Blood Cell Extracellular Vesicle-Based Drug Delivery: Challenges and Opportunities

Extracellular vesicles: Natural liver-accumulating drug delivery vehicles for the treatment of liver diseases

CRISPR delivery with extracellular vesicles: Promises and challenges

Efficient Delivery of Mrna Using Crosslinked Nucleic Acid Nanogel As a Carrier

Non-viral delivery of RNA for therapeutic T cell engineering

Drug delivery systems for RNA therapeutics

Protein-based delivery systems for RNA delivery

Development of non-viral targeted RNA delivery vehicles – a key factor in success of therapeutic RNA

Small extracellular vesicles (sEVs)-based gene delivery platform for cell-specific CRISPR/Cas9 genome editing

Extracellular Vesicles as New Players in Drug Delivery: A Focus on Red Blood Cells-Derived EVs

Exosome-Based Carrier for RNA Delivery: Progress and Challenges